Life Sciences & Chemistry

Are you a founder in the field of life science and chemistry and on the lookout for financing? At HTGF, we not only offer you investment know-how, but also understand your specific needs and provide you with the right expertise to support your business ideas. We leverage our tailored network to help you achieve success.

Many steps must be taken to become a successful start-up

Our Life Sciences & Chemistry team has the required start-up spirit! We have both entrepreneurial expertise and an understanding of science, medicine and practical applications. Having invested in over 200 life science and chemical companies since 2005, we know what really matters.

With our expertise and passion, we are at your side as a sparring partner from seed to exit – whether it be in the field of drug development and biotech, medtech and diagnostics, digital health, R&D tools or chemistry.

The right tools

We offer you the right tools to meet your individual challenges as a founder of a life sciences and chemical start-up:

We help you get started

  • Fast and flexible seed financing
  • Matching with co-investors from our international network
  • Communication on an equal footing
  • Inspiration and knowledge transfer

Let’s develop and grow together

  • Support in the acquisition of follow-up financing
  • Exchanges with founders and our partners from research, industry and SMEs
  • Close connection with cooperation partners

A shared path – from seed to exit

  • Support in finding the most suitable M&A advisors
  • Support in negotiations and due diligence
  • Assistance with company valuations and incentives
  • Transaction security from trade sale to IPO
  • Access to the HTGF network with many potential buyers

Who we are

What you can expect from us

  • From the very early stage to the exit, we support you as partners with our know-how and understanding of your needs.
  • We have an entrepreneurial spirit – many of us have founded our own companies and we have the necessary appetite for risk
  • We understand how financing works and can call on our network
  • We have backgrounds as scientists and know the pitfalls: manufacturing/CMC, regulatory affairs, market access, team growth, business development, etc.

The areas we invest in include:

  Pharma/biotech

  Medtech

  R&D tools

  Diagnostics

  Digital health

  Chemistry

Our Life Sciences & Chemistry Portfolio 

Let’s turn ideas into reality!

Societal challenges, such as diseases or advancing climate change, require innovative solutions. And this is why pioneering start-ups in the fields of life sciences and healthcare, chemistry, food and agricultural technology, and new materials are playing a crucial role.

Germany has the platform to continue launching successful high-tech start-ups:

  • Top-class research at universities and institutes
  • Close cooperation between industry and consumers
  • Transfer-enabling support

With your innovative start-up ideas, we can create sustainable and disruptive solutions together – what are we waiting for?

Looking to start a business? Contact our team here.

Is your pitch deck complete? Upload it here!

Topics that might interest you

Press
23. April 2024

Cultimate Foods raises 2.3 million EUR seed funding from leading Biotech and Foodtech investors to revolutionize the alternative meat industry

BERLIN, April 23, 2024 – Cultimate Foods, a biotech startup based in Berlin’s Biocube and Hannover (Institut für Technische Chemie, Leibniz Universität Hannover), successfully closes its seed round to scale up production processes, expand commercial collaborations and operation. The 2.3 million EUR round was led by High-Tech Gründerfonds (HTGF), one of Europe’s leading seed investors. HTGF was joined by the Life Science ValleyWachstumsfonds, b.value AG and Kale United. Le
 
Press
25. March 2024

Successful exit for HTGF: Novo Nordisk to acquire Cardior Pharmaceuticals

Novo Nordisk will acquire Cardior for up to 1.025 billion Euros in upfront and potential milestone payments. Cardior is a leader in the discovery and development of therapies that target RNA as a means to prevent, repair and reverse diseases of the heart. High-Tech Gründerfonds (HTGF), one of Europe’s leading seed investors, participated in the first financing round in 2017. Bonn, Germany, 25 March 2024 – Novo Nordisk and Cardior Pharmaceuticals today announced that N
 
Press
14. March 2024

Tubulis Closes Upsized €128 Million Series B2 to Accelerate Clinical Development of Solid Tumor-Focused ADC Pipeline

Financing round co-led by EQT Life Sciences and Nextech Invest [1], with participation from current and new leading global biotechnology investors Proceeds will support clinical evaluation of lead solid tumor ADC candidates, TUB-030 and TUB-040, further technology development and expansion into the US MUNICH, GERMANY, March 14, 2024 – Tubulis today announced the successful completion of an upsized and oversubscribed €128 million ($138.8 million) Series B2 financing. The round
 
Press
12. March 2024

Breathing through the gut: MedTech startup O11 biomedical secures EIC Accelerator Grant and seed funding to accelerate growth.

Aachen-based MedTech start-up O11  uses the human gut as an alternative respiratory organ to improve the survival rate and quality of life of patients with severe respiratory distress. O11 successfully closed a seed financing round with High-Tech Gründerfonds and secured an EIC Accelerator Grant. Product RESPILIQ is rapidly approaching market approval. Aachen, March 12, 2024 – Aachen-based medical technology start-up O11 biomedical GmbH secured its first seed finan
 
Press
20. February 2024

Altavo concludes Series A for the development of its Artificial Voice

February 20, 2024 – Altavo, a startup in AI-based voice rehabilitation founded in 2021, successfully closed its Series A financing round on February 1, 2024. A European consortium led by OCCIDENT is investing € 5.0m in the development of Altavo’s novel Artificial Voice. Altavo’s Artificial Voice is a medical device designed to help voiceless people, for example after laryngectomy or during mechanical ventilation, regain their own, natural sounding voice. The proprietary “sil
 
Dräger GWA Hygiene BB
Blog
18. May 2022

GWA Hygiene and Dräger: From collaboration to investment

How does a company specialized in medical and safety technology with a more than 130-year history end up getting together with a six-year-old start-up? Common goals, collaboration on an equal footing and good partners are key aspects in this regard. That is at least according to Jens Altmann, President Business Unit Data Business at Dräger, and Tobias Gebhardt, CEO at GWA Hygiene. Dräger, a global corporation, recently invested in High-Tech Gründerfonds (HTGF) portfolio company GWA Hygien